Test Price
2,800 AED✅ Home Collection Available
UBQLN2 Gene Analysis (Amyotrophic Lateral Sclerosis, X-Linked Juvenile & Adult-Onset) Genetic Test in UAE | 2800 AED | DHA Licensed Facility
Executive Summary & Core Metrics
Executive Overview
- Diagnostic Accuracy: 99.9% analytic sensitivity and specificity via ISO-accredited sequencing with orthogonal Sanger confirmation.
- Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Post-Test Support: Telephonic clinical guidance from a Consultant Medical Geneticist to interpret results and discuss familial implications.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Price
2,800 AED
Turnaround Time
3–4 Weeks
Specimen Type
Peripheral Whole Blood
DHA License
No. 1143
Test Overview & Methodology
The UBQLN2 gene test utilizes next-generation sequencing (NGS) with Sanger confirmation to detect pathogenic variants associated with X-linked juvenile and adult-onset amyotrophic lateral sclerosis (ALS). This molecular analysis targets coding exons and flanking intronic regions of the UBQLN2 gene to identify disease-causing mutations that impair ubiquitin-proteasome pathway function in motor neurons. Results assist neurologists and genetic counselors in confirming diagnosis, stratifying familial risk, and guiding reproductive planning. The assay is performed under ISO 9001:2015 quality management standards within a DHA-licensed laboratory facility.
| Feature | Our Test (DHA-Certified) | Alternative (Research-Only NGS) |
|---|---|---|
| Precision | 99.9% analytic sensitivity & specificity | Variable quality, no clinical validation |
| Method | NGS + Sanger confirmation, ISO 9001:2015 | NGS without orthogonal confirmation |
| Turnaround Time | 3–4 weeks (guaranteed) | 6–8 weeks, uncertain |
| Clinical Validity | Clinically validated with phenotype correlation | Research use only, not diagnostic |
Physician Insight & Safety Protocols
"A positive UBQLN2 mutation confirms the molecular basis of X-linked ALS; however, the result must be interpreted within the full clinical context including neurological exam findings, family pedigree, and disease progression trajectory. Mandatory pre-test and post-test genetic counseling ensures that patients and families understand the implications for prognosis, recurrence risk, and reproductive options." — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
Important Clinical Precautions
- Do not alter or discontinue any prescribed medications, including riluzole or other ALS therapies, without direct consultation with your treating neurologist.
- This genetic test is an adjunct to clinical diagnosis and does not replace comprehensive neurological evaluation or ongoing symptom management.
- Results may take 3–4 weeks to finalize; continue all current treatments and monitoring during this period.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion Criteria
- Inability to provide informed consent (minors require legal guardian consent per UAE Federal Law).
- Failure to complete mandatory pre-test genetic counseling session.
- Active acute respiratory distress, severe dysphagia, or rapidly progressive neuromuscular decline requires immediate emergency care before testing.
Patient FAQ & Clinical Guidance
1. What does the UBQLN2 gene test detect and why is it performed?
Answer: This test identifies pathogenic mutations in the UBQLN2 gene to confirm a clinical suspicion of X-linked amyotrophic lateral sclerosis (ALS). It is performed when a patient presents with progressive motor weakness, has a family history suggestive of X-linked inheritance, or requires definitive molecular diagnosis for prognosis and family risk assessment.
2. How is the sample collected and what is the turnaround time?
Answer: A certified phlebotomist collects a peripheral whole blood sample at your home via VIP Mobile Phlebotomy between 8 AM and 11 PM daily. Results are delivered within 3–4 weeks from sample receipt at the DHA-licensed laboratory.
3. Is genetic counseling required before and after testing?
Answer: Yes. A mandatory pre-test genetic counseling session is conducted to draw a three-generation pedigree, explain inheritance patterns, and obtain fully informed consent. Post-test counseling is also provided to discuss results, recurrence risks, and reproductive options in accordance with UAE healthcare regulations.
4. What does a positive or negative result mean for my family?
Answer: A positive result confirms the genetic basis of ALS and indicates that first-degree relatives may be at risk and should consider predictive testing after counseling. A negative result reduces but does not entirely exclude a genetic cause, as other genes may be involved. Genetic counselors will guide family testing decisions.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Data Protection: All genetic and personal data are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring encrypted storage, controlled access, and patient consent management.
- Health Information Governance: Laboratory operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing the secure handling of electronic health records and diagnostic data.
- DHA Licensing: The laboratory operates under DHA Facility License Number 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE, with routine inspections and quality audits.
- Patient Rights: All testing is conducted under the principles of informed consent and medical liability protections as outlined in Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | UBQLN2 Gene Analysis (Amyotrophic Lateral Sclerosis, X-Linked Juvenile & Adult-Onset) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (21–28 calendar days) |
| Sample Type / Matrix | Peripheral Whole Blood (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation, ISO 9001:2015 |
| ICD-10-CM Code | G12.21 (Amyotrophic lateral sclerosis) |
| LOINC Code | 81265-2 (UBQLN2 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians